If you have been reading about PPARδ agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
This relates to having an increased risk of a woman bearing fraternal twins because higher levels of FSH will produce more eggs. The more eggs a woman produces increases the chance of multiple eggs ovulating and becoming fertilized by sperm. In retrospect, depending on the type of variation, the FSHB gene could potentially cause infertility by the inability to produce enough FSH, in both males and females. Additionally, low or no FSH can result in delayed puberty and risk of disease. Diseases associated with FSHB variants are hypogonadism, hypogonadotropic hypogonadism type 24 (HH24), and type 7 (HH7), and are possibly linked to polycystic ovary syndrome.
== Definition == According to the updated 2014 AAOMS position paper (modified from 2009), in order to distinguish MRONJ, the working definition claims patients may be considered to have MRONJ if all the following characteristics are present:
In Australia, iced coffee may include syrup, cream, cocoa powder or coffee beans. The café style is something like an unblended milkshake, and may be made from espresso coffee or only coffee flavoring. Bushells has marketed a Coffee and Chicory Essence since the late 19th century, as has Bickfords since 1910. There are many brands of packaged iced coffee consisting of coffee, milk, and sweetener. In South Australia, Farmers Union Iced Coffee has outsold Coca-Cola and is one of the state's biggest brands. Pauls "Territory's Own" Iced Coffee is popular in the Northern Territory and Norco Real Iced Coffee is prominent in Northern New South Wales and South East Queensland. Other brands include Breaka, Big M, Brownes Chill, Moove, Masters, Dare, Max, Fleurieu, Rush, Oak and Ice Break.
It has local production plants in Bologna and Florence in Italy along with other manufacturing sites in Germany, France, Switzerland, Spain, United Kingdom, U.S.A., India, Malaysia and China. More than 5,000 are employed in the company, 2,600 of those work abroad. Its annual turnover in 2016 was €1.310,55 million. Its employees number more than 5,000 (with about 2,600 outside of Italy) in 41 manufacturing sites in Italy, Germany, France, Switzerland, Spain, the UK, the US, India, Malaysia, China and Argentina. Its sales network covers more than 80 countries. The Group has around 6,000 employees, of which over 2,800 overseas, and has 45 production plants in Italy, Germany, France, Switzerland, Spain, United Kingdom, United States, India, Malaysia, China and Argentina. IMA has an extensive commercial network, which consists of 29 branches with sales and assistance services in Italy, France, Switzerland, United Kingdom, Germany, Austria, Spain, Poland, Israel, Russia, United States, India, China, Malaysia, Thailand and Brazil, representative offices in Central and Eastern European countries and more than 50 agencies covering a total of about 80 countries. In addition, in 2019, it had a turnover of 1,595.5 million euros, of which about 90% outside Italy.
=== Topical and procedural therapies === Topical therapies are used mainly for cosmetic reasons. Small clinical studies have reported improvement with topical retinoids, urea preparations and other keratolytic agents, although evidence remains limited and results vary among individuals. Topical treatment does not modify the underlying cause of AN. Procedural interventions, including fractional carbon dioxide (CO2) laser and various chemical peels, have been explored in pilot studies and small comparative trials. A randomized controlled trial involving 38 participants reported that fractional CO2 laser resulted in greater reduction of lesion severity compared with retinoic-acid peel; however, the study was short-term and limited in size. Procedural therapies generally require specialised equipment, and availability and cost may limit use.
Sources: en.wikipedia.org
=== Free testosterone === Lipophilic hormones (soluble in lipids but not in water), such as steroid hormones, including testosterone, are transported in water-based blood plasma through specific and non-specific proteins. Specific proteins include sex hormone-binding globulin (SHBG), which binds testosterone, dihydrotestosterone, estradiol, and other sex steroids. Non-specific binding proteins include albumin. The part of the total hormone concentration that is not bound to its respective specific carrier protein is the free part. As a result, testosterone which is not bound to SHBG is called free testosterone. Only the free amount of testosterone can bind to an androgenic receptor, which means it has biological activity. While a significant portion of testosterone is bound to SHBG, a small fraction of testosterone (1%-2%) is bound to albumin and the binding of testosterone to albumin is weak and can be reversed easily; as such, both albumin-bound and unbound testosterone are considered to be bioavailable testosterone. This binding plays an important role in regulating the transport, tissue delivery, bioactivity, and metabolism of testosterone. At the tissue level, testosterone dissociates from albumin and quickly diffuses into the tissues. The percentage of testosterone bound to SHBG is lower in men than in women. Both the free fraction and the one bound to albumin are available at the tissue level (their sum constitutes the bioavailable testosterone), while SHBG effectively and irreversibly inhibits the action of testosterone.
Trump stated that Hegseth ordered the strike that morning. Two of those killed may have been citizens of Trinidad and Tobago. On 24 October, Hegseth announced "the first strike at night" against a vessel allegedly operated by Tren de Aragua in the Caribbean, killing six people on board.
These include hypothetical machines that manipulate individual atoms and machines with organism-like self-replicating abilities, mobility, ability to consume food, and so forth. These are quite different from devices that merely (as defined above) "guide chemical reactions by positioning reactive molecules with atomic precision". Because synthetic molecular assemblers have never been constructed and because of the confusion regarding the meaning of the term, there has been much controversy as to whether "molecular assemblers" are possible or simply science fiction. Confusion and controversy also stem from their classification as nanotechnology, which is an active area of laboratory research which has already been applied to the production of real products; however, there had been, until recently, no research efforts into the actual construction of "molecular assemblers". Nonetheless, a 2013 paper by David Leigh's group, published in the journal Science, details a new method of synthesizing a peptide in a sequence-specific manner by using an artificial molecular machine that is guided by a molecular strand. This functions in the same way as a ribosome building proteins by assembling amino acids according to a messenger RNA blueprint. The structure of the machine is based on a rotaxane, which is a molecular ring sliding along a molecular axle. The ring carries a thiolate group, which removes amino acids in sequence from the axle, transferring them to a peptide assembly site.
The improved safety and tolerability profile of the SSRIs in patients with MDD, compared with TCAs and MAOIs, represented yet another important advance in the treatment of depression. Since the late 1980s, SSRIs have dominated the antidepressant drug market. Today, there is increased interest in antidepressant drugs with broader mechanisms of action that may offer improvements in efficacy and tolerability. In 1993, a new drug was introduced to the US market called venlafaxine, a serotonin–norepinephrine reuptake inhibitor. Venlafaxine was the first compound described in a new class of antidepressant substances called phenylethylamines. These substances are unrelated to TCA and other SSRIs. Venlafaxine blocks the neuronal reuptake of serotonin, norepinephrine, and, to a lesser extent, dopamine in the central nervous system. In contrast with several other antidepressant drugs, venlafaxine can induce a rapid onset of action mainly due to a subsequent norepinephrine reuptake inhibition. See timeline in figure 1.
=== Plant screening program === In 1955, the NCI in the United States set up the Cancer Chemotherapy National Service Center (CCNSC) to act as a public screening center for anticancer activity in compounds submitted by external institutions and companies. Although the majority of compounds screened were of synthetic origin, one chemist, Jonathan Hartwell, who was employed there from 1958 onwards, had experience with natural product derived compounds, and began a plant screening operation. After some years of informal arrangements, in July 1960, the NCI commissioned the United States Department of Agriculture (USDA) botanists to collect samples from about 1,000 plant species per year. On 21 August 1962, one of those botanists, Arthur S. Barclay, collected bark from a single Pacific yew tree in a forest north of the town of Packwood, Washington, as part of a four-month trip to collect material from over 200 different species. The material was then processed by a number of specialist CCNSC subcontractors, and one of the tree's samples was found to be cytotoxic in a cellular assay on 22 May 1964. Accordingly, in late 1964 or early 1965, the fractionation and isolation laboratory run by Monroe E. Wall in Research Triangle Park, North Carolina, began work on fresh Taxus samples, isolating the active ingredient in September 1966 and announcing their findings at an April 1967 American Chemical Society meeting in Miami Beach. They named the pure compound taxol in June 1967. Wall and his colleague Wani published their results, including the chemical structure, in 1971.
Sources: en.wikipedia.org
Methysticin is one of the six major kavalactones found in the kava plant. It enhances the activity of the GABAA receptor, acting as a positive modulator without affecting the benzodiazepine binding site. This effect is attributed to structural features such as its angular lactone ring and is similar in strength to other kavalactones like kavain and dihydromethysticin. Methysticin also induces the liver enzyme CYP1A1, which plays a role in the toxification of benzo[a]pyrene into a highly carcinogenic metabolite. However, such induction has not been observed in vivo in humans or animals. Additionally, methysticin is a mechanism-based inactivator of CYP2C9, irreversibly inhibiting the enzyme through NADPH-dependent reactive intermediates, suggesting potential interactions with medications metabolized by CYP2C9.
=== Asia === Internal border controls exist in many parts of Asia. For example, travellers visiting minority regions in India and China often require special permits to enter. Internal air and rail travel within non-autonomous portions of India and mainland China also generally require travel documents to be checked by government officials as a form of interior border checkpoint. For such travel within India, Indian citizens may utilise their Voter ID, National Identity Card, passport, or other proof of Indian citizenship, whilst Nepali nationals may present any similar proof of Nepali citizenship. For such travel within mainland China, Chinese nationals must use their national identity cards.
poly(A) tail A post-transcriptional modification consisting of a chain of repeated adenosine residues, 40–250 nucleotides in length, attached to the 3' end of nearly all mature eukaryotic messenger RNA transcripts (those of histones being a notable exception).
Azvudine is an antiviral drug which acts as a reverse transcriptase inhibitor. It was discovered for the treatment of hepatitis C and has since been investigated for use against other viral diseases such as AIDS and COVID-19, for which it was granted conditional approval in China. Azvudine was first discovered in 2007. It costs 350 Chinese yuan per 7 days for COVID, as of November 2022.
==== Companion of the Order of St Michael and St George (CMG) ==== Jennifer Elizabeth Anderson, Director, Consular and Crisis, Foreign, Commonwealth and Development Office. For services to British Foreign Policy and to British Nationals Overseas. Zamir Nicholas Catasaras, Director General for Russia and Ukraine, Cabinet Office. For services to British Foreign Policy. Roger James Coventry, Criminal Justice Adviser. For services to Justice and Stability overseas. Colin Mark Evans, Director General, Foreign, Commonwealth and Development Office. For services to National Security. Dr Fiona Hill, Senior Fellow, Brookings Institution, Washington D.C., United States of America. For services to International Relations. Dr Rurik Miles Marsden, , Development Director, British Embassy Yangon, Myanmar. For services to International Development. Susanna Mary Davies Moorehead, lately Chair, Development Assistance Committee, The Organisation for Economic Co-operation and Development (OECD). For services to International Development and Diplomacy. Jane Anne Nelson, Director, Corporate Responsibility Initiative, Kennedy School of Government, Harvard University, United States of America. For services to Business and to Sustainability. Dr Sara Pantuliano, Chief Executive, ODI. For services to Peacebuilding, to Humanitarian Assistance and to International Development. Simon Penny, lately H.M. Trade Commissioner for the Middle East and Pakistan and H.M. Consul General to Dubai and the Northern Emirates. For services to International Trade and Investment.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.